Summary What is already known about this topic? COVID-19 vaccines have been effective in preventing SARS-CoV-2 infection and associated hospitalizations and deaths among nursing home residents. What is added by this report? In a large cohort of nursing home residents, receipt of a second mRNA COVID-19 booster dose during circulation […]
Read More
Unvaccinated children ages 5 to 11 were more than twice as likely to be hospitalized for COVID-19 during the Omicron wave, and nearly a third of hospitalized kids overall had no underlying medical conditions while about a fifth required intensive care unit (ICU) admission, researchers found. From Dec. 19, 2021 […]
Read More
Summary What is already known about this topic? Persons with previous SARS-CoV-2 infection have some protection against reinfection leading to hospitalization, but there is limited evidence regarding the additional benefit of vaccination among these persons. What is added by this report? Among persons with previous infection, COVID-19 mRNA vaccination provided […]
Read More
Question Among patients at risk of disease progression, does early treatment of mild to moderate COVID-19 with the neutralizing antibody sotrovimab prevent progression to severe disease? Findings In this randomized clinical trial of 1057 participants, treatment with a single intravenous dose of sotrovimab, compared with placebo, resulted in a statistically significant reduction […]
Read More
Within weeks, the Omicron variant has fueled thousands of new COVID-19 hospitalizations among U.S. children, raising new concerns about how the many unvaccinated Americans under the age of 18 will fare in the new surge. The seven-day-average number of daily hospitalizations for children between Dec. 21 and Dec. 27 is […]
Read More
Extended anticoagulation with low-dose rivaroxaban (Xarelto, Bayer/Janssen) after hospitalization for COVID-19 may reduce the risk of venous thromboembolism (VTE) without worsening the risk of bleeding in patients who had been considered high-risk for VTE, a multicenter randomized trial suggests. The primary efficacy outcome occurred in five (3%) patients assigned to rivaroxaban and 15 (9%) […]
Read More
Extended anticoagulation with low-dose rivaroxaban (Xarelto, Bayer/Janssen) after hospitalization for COVID-19 may reduce the risk of venous thromboembolism (VTE) without worsening the risk of bleeding in patients who had been considered high-risk for VTE, a multicenter randomized trial suggests. The primary efficacy outcome occurred in five (3%) patients assigned to rivaroxaban and 15 (9%) […]
Read More
Summary What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of […]
Read More
Summary What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of […]
Read More
Remdesivir (Veklury, Gilead) was found to reduce some COVID-19 patients’ risk of hospitalization by 87% in a phase 3 trial, the drug’s manufacturer announced Wednesday in a press release. The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of a 3-day course of intravenous remdesivir in an analysis of 562 nonhospitalized […]
Read More
